drugset / Trial / NCT07838649
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
Phase 1
Not yet recruiting
36 enrolled
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Timeline
- Start
- 2026-11-01
- Primary completion
- 2029-12-12
- Completion
- 2029-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 370 mbq | Intravenous |
| Subject | 68Ga-Galmydar | Diagnostic / imaging agent | 92.5 mbq | Intravenous |